Umeda T, Ishii T, Hatakeyama K, Wakita H
Dept. of Orthopedic Surgery, National Cancer Hospital East.
Gan To Kagaku Ryoho. 1993 Oct;20(13):1937-44.
The role of chemotherapy for soft tissue sarcoma with the exception of rhabdomyosarcoma remains controversial. Several randomized trials have suggested only doxorubicin (ADR) and ifosfamide produced a single-agent response rate above 20% in advanced sarcoma. As a combination chemotherapy, the doxorubicin-based combination, ADR + DTIC (ADIC) and CYVADIC, showed a higher response rate. Ifosfamide in addition to doxorubicin (Ifos + ADR or ADIC) appeared to have major activity with a higher complication rate. The role and value of adjuvant chemotherapy have not yet been established. Most randomized studies have suggested that no survival benefit was observed in the chemotherapy group relative to the control group. Further basic and clinical investigation is necessary to obtain a better prognosis in high-grade malignant soft tissue sarcoma.
除横纹肌肉瘤外，化疗在软组织肉瘤中的作用仍存在争议。多项随机试验表明，在晚期肉瘤中，只有阿霉素（ADR）和异环磷酰胺的单药有效率高于20%。作为联合化疗，以阿霉素为基础的联合方案ADR + DTIC（ADIC）和CYVADIC显示出更高的有效率。除阿霉素外使用异环磷酰胺（Ifos + ADR或ADIC）似乎具有主要活性，但并发症发生率更高。辅助化疗的作用和价值尚未确立。大多数随机研究表明，化疗组相对于对照组未观察到生存获益。为了在高级别恶性软组织肉瘤中获得更好的预后，有必要进行进一步的基础和临床研究。
